Bayer's Prostate Cancer Drug Earns FDA Approval August 2, 2019 The U.S. Food and Drug Administration (FDA) approved Bayer’s Nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer (nmCRPC). The clinical trial evaluated Nubeqa (an androgen receptor inhibitor - ARI) plus androgen deprivation therapy (ADT) and the trial showed highly significant improvement in metastasis-free survival (MFS).Read the full article here.Source: BioSpace.com Prostate Cancer News
The U.S. Food and Drug Administration (FDA) approved Bayer’s Nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer (nmCRPC). The clinical trial evaluated Nubeqa (an androgen receptor inhibitor - ARI) plus androgen deprivation therapy (ADT) and the trial showed highly significant improvement in metastasis-free survival (MFS).Read the full article here.Source: BioSpace.com
Complete the Survey
